OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
2.390
+0.130 (5.75%)
At close: Aug 29, 2025, 4:00 PM
2.330
-0.060 (-2.51%)
After-hours: Aug 29, 2025, 6:46 PM EDT
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,250,384
Market Cap
76.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OSTX News
- 2 days ago - OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 - Newsfile Corp
- 3 days ago - OS Therapies Terminates Equity Line of Credit - Newsfile Corp
- 10 days ago - OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 15 days ago - OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025 - Newsfile Corp
- 22 days ago - OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 22 days ago - OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 6 weeks ago - OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer - Newsfile Corp
- 7 weeks ago - OS Therapies Provides Clinical & Global Regulatory Updates - Newsfile Corp